Objective To compare the e¤cacy and tolerability of meropenem and imipenem/cilastatin as empirical monotherapy in intensive care unit (ICU) patients with serious bacterial infections.
INTRODUCTION
Serious bacterial infections are common in patients in the intensive care unit (ICU) and they result in considerable morbidity and mortality. Approximately 45% of the 10,038 ICU patients included in the European Prevalence of Infection in Intensive Care (EPIC) Survey of 1992 had at least one bacterial infection [1] . Pneumonia and other lower respiratory tract infections (LRTIs) were the most prevalent infections (64.7%), followed by urinary tract (17.6%) and bloodstream infections (12.0%).The most frequently reported bacterial isolates were Enterobacteriaceae (mainly Escherichia coli, Klebsiella spp. and Enterobacter spp.), Staphylococcus aureus, Pseudomonas aeruginosa and coagulase-negative staphylococci. Fifty-¢ve per cent of ICU-acquired infections were polymicrobial.
In this setting, empirical antibiotic treatment must therefore have a broad spectrum of antibacterial activity, covering Gram-positive and Gram-negative aerobes and anaerobes. Traditionally, this has been achieved by using combinations of antibiotics, usually a b-lactam agent (e.g. a third-generation cephalosporin) plus an aminoglycoside or antianaerobic agent. However, the usefulness of many b-lactams, including the third-generation cephalosporins, is threatened by the spread of plasmid-mediated, extended-spectrum b-lactamases (ESBLs) in Enterobacteriaceae [2] . Up to 23% of Klebsiella isolates from European ICUs may produce these enzymes [3] . Furthermore, over-expression of inducible group I b-lactamases by Enterobacter, Citrobacter, Serratia and Pseudomonas spp. compromises the activity of cephalosporins and b-lactam/blactamase inhibitor combinations, while constitutive hyperproducers are readily selected during therapy with these agents [4] .
The carbapenems possess the widest antibacterial spectra and greatest b-lactamase stability of all b-lactams, and therefore these agents o¡er a realistic option for monotherapy in serious bacterial infections. The only two carbapenems available outside Japan, meropenem and imipenem/cilastatin, are active against most clinically important pathogens and are stable to the vast majority of serine-based b-lactamases (including ESBLs and Bush Group I enzymes) [5, 6] . However, important di¡erences exist between the two compounds [7] , which may favor the use of meropenem in the ICU setting. These include the greater in vitro activity of meropenem against the predominant Gram-negative pathogens [5] and its stability to renal dehydropeptidase-I (DHP-I), which permits its administration without a DHP-I inhibitor such as cilastatin (which can accumulate in renal failure [8] ). In addition, meropenem is well tolerated by the central nervous system (CNS) with regard to seizures [7] and can be administered by bolus intravenous injection.
This study compared the e¤cacy and tolerability of meropenem and imipenem/cilastatin as empirical monotherapy in ICU patients with serious bacterial infections.
MATERI ALS AND METHODS
This was a multicenter, open-label, randomized, parallelgroup trial conducted in Belgium to compare intravenous meropenem and imipenem/cilastatin in ICU patients with severe or life-threatening infections caused by sensitive pathogens.
Patients
These comprised ICU adults (aged r18 years) requiring parenteral antibacterial therapy for one or more of the following infections: LRTI (in mechanically ventilated patients), intraabdominal infections and sepsis. For eligibility, at least one responsible pathogen isolated at study entry had to be susceptible to both study drugs. In patients with multiple infection sites, the most serious was designated as the primary site, and additional sites were ranked in order of importance. This trial gained local Ethics Committee approval, and informed consent was obtained from all patients or their next of kin.
Patients were excluded if they were pregnant or breastfeeding, if they had a hypersensitivity to any b-lactam, if they suffered from hepatic impairment, neutropenia or cystic ¢brosis, or if they had a history of CNS disease or other disorder likely to cause convulsions. Patients with severe underlying disease who were unlikely to complete at least 48 h of study treatment were excluded, as were those receiving probenecid. Patients with secondary infections at sites other than those speci¢ed above were also ineligible. Patients could only enter the trial once.
Therapeutic regimen
Patients were randomized to receive either meropenem or imipenem/cilastatin, each administered intravenously at a dosage of 1 g every 8 h. Randomization was strati¢ed according to the three types of primary infection. Meropenem was administered either as a bolus injection or as an infusion over a period of 20^30 min. Imipenem/cilastatin was infused over 40^60 min (or at a slower rate if the patient experienced nausea or vomiting). Since both study drugs are chie£y eliminated renally, their dosages were adjusted according to the degree of renal impairment. An additional dose of study drug was given after hemodialysis.The recommended duration of therapy was 5^10 days (maximum 28 days). Treatment for a minimum of 48 h was required for the assessment of e¤cacy. No other antibacterials were allowed during the study, except in the event of surgical prophylaxis or treatment failure.
Clinical assessment
The overall condition of the patient at entry was assessed using the Acute Physiology and Chronic Health Evaluation (APACHE II) scoring system [9] . Clinical signs and symptoms associated with infection were evaluated within 3 days prior to commencing treatment and daily during treatment.
Sepsis was de¢ned as a clinical entity characterized by one or more of the following signs and symptoms [10] : fever (> 38.3 C), chills, leukocytosis, hyperventilation, hypothermia, skin lesions, septic embolism, change in mental status, hypotension, disseminated intravascular coagulation (DIC) and organ failure.
Intra-abdominal infections were described as either abscesses or peritonitis originating from the following intraabdominal organs: stomach, duodenum, biliary tract, pancreas, appendix, small intestine and colon.
For LRTI to be diagnosed, the following signs and symptoms had to be present: pulmonary in¢ltration thought to be due to infection on chest X-ray and at least two of the following criteriaöpurulent sputum (< 10 squamous epithelial cells, > 25 white blood cells, and a pathogen should be cultured), fever and leukocytosis. The respiratory sample should áñä Verwaest Meropenem versus imipenem/cilastatin in serious infections be obtained by endotracheal aspirate, bronchoalveolar lavage, protected specimen brush, pleural £uid or lung biopsy.
Hospital-acquired infections were de¢ned as late-onset infections (> 72 h) or any postoperative infections, whereas community-acquired infections were of early onset (< 72 h).
The clinical response was assessed at the end of treatment or at the time when additional antibiotics or antifungals were added in the event of treatment failure and/or upon the development of new infections or superinfections. Clinical response was classi¢ed as cured (complete remission of local and systemic signs and symptoms), improved (improvement of local and systemic signs and symptoms but without complete resolution) or unchanged/worse (no improvement or deterioration of signs and symptoms). If relevant, clinical response was reassessed at a follow-up examination 2^4 weeks post-treatment. At follow-up, clinical response could also be classi¢ed as relapse (initial cure/improvement followed by a general decline and worsening of the clinical condition).
The clinical response was considered satisfactory if the patient was cured or improved, and unsatisfactory if the patient was unchanged/worse or experienced a relapse.
The tolerability of the study drugs was assessed by monitoring adverse events and routine clinical laboratory tests.
Bacteriologic assessment
Cultures were obtained from sites appropriate to the infection immediately (or within 3 days) prior to starting treatment, during treatment if clinically indicated, preferably immediately after study treatment was discontinued or changed, and at 2^4 weeks follow-up, if possible.
Acceptable specimens from patients with intra-abdominal infections included peritoneal £uid, drain £uid, abscess material or pus. For patients with LRTI, endotracheal aspirates, bronchoalveolar lavage or protected specimen brush samples, abscess material, pleural £uid and hemocultures or blood cultures were accepted.Two blood cultures, preferably from separate sites or from an intra-arterial line (taken at least 30 min apart), were collected before treatment from patients with suspected sepsis. Susceptibility testing was performed according to standard accepted disk sensitivity criteria [11] .
Disks loaded with meropenem (10 mg) or Rosco tablets of meropenem were provided by AstraZeneca Pharmaceuticals for sensitivity testing using Kirby^Bauer (or equivalent) determinations. Commercially available disks or tablets were used for sensitivity testing of imipenem for assessment of comparative activity.
Resistance to meropenem was de¢ned as a zone size of 11 mm, and resistance to imipenem as a zone size of 13 mm (13 mm and 16 mm, respectively, for Rosco tablets).
The bacteriologic response was assessed at the end of the therapy (or at the time when additional antibiotics were given for treatment failure or new infections) and at follow-up, if possible.
The response was considered satisfactory when the original pathogen(s) were eradicated or presumed eradicated (i.e. when further sampling was not considered justi¢ed because of clinical cure/improvement). The response was considered unsatisfactory if the primary pathogen persisted (or was presumed to have persisted) or if a new pathogen isolated at the original infection site during study therapy required antibacterial treatment (i.e. superinfection occurred). At follow-up, the bacteriologic response could also be classi¢ed as relapse.
Statistical methods
The primary endpoint was the percentage of patients in each treatment group with a satisfactory clinical response at the end of randomized treatment. A satisfactory response rate of 85% was assumed for imipenem/cilastatin. To demonstrate equivalence between meropenem and imipenem/cilastatin, the upper 95% con¢dence interval (CI) (a 0.05) for the di¡er-ence between response rates was not to exceed 15%. In order to ensure a power of 80% (b 0.20), 90 fully evaluable patients were required in each group. Since only 85% of randomized patients were expected to be evaluable for response, we aimed to recruit a total of approximately 210 patients.
Secondary endpoints included the satisfactory clinical response rate at the end of treatment in bacteriologically evaluable patients, and the bacteriologic response at the end of treatment for evaluable patients. In addition, a subgroup analysis according to the type of infection was performed.
For each endpoint, the proportions of patients with a satisfactory response in each group were compared using a chisquare test. The di¡erence in proportions was estimated, together with 95% CI (calculated using a normal approximation), and statistical signi¢cance determined using the chisquare test.
RESULTS

Patients
A total of 212 patients entered the study, 107 in the meropenem group and 105 in the imipenem/cilastatin group. The demographic and baseline clinical characteristics of the two groups were similar (Table 1 ). The mean APACHE II score was slightly higher in the meropenem group than in the imipenem/cilastatin group, as was the number of patients who had received previous antibacterial therapy. The majority of patients (66.9%) were mechanically ventilated. LRTI was the most common infection diagnosis, followed by intra-abdominal infection and sepsis. The mean (þ Standard Deviation (SD)) durations of treatment in the meropenem and imipe-
nem/cilastatin groups were 9.8 þ 4.9 days and 9.8 þ 5.3 days, respectively. Almost 60% of the meropenem patients received drug by bolus injection.
Twenty patients were excluded from the analysis due to protocol violations (Figure 1) , leaving 192 evaluable patients (94 meropenem, 98 imipenem/cilastatin). Of these, 178 (87 meropenem, 91 imipenem/cilastatin) were evaluable for clinical response at the end of treatment, and 146 (73 meropenem, 73 imipenem/cilastatin) were evaluable for bacteriologic response at the end of treatment. The reasons for clinical nonevaluability are outlined in Figure 1 .
Ef®cacy
Among evaluable patients, the overall satisfactory clinical response rates at the end of randomized treatment were 77.0% (67/87) in the meropenem group and 68.1% (62/91) in the imipenem/cilastatin group (di¡erence 8.9%; 95% CI À4.2% to 21.9%; P 0.185). Meropenem and imipenem/cilastatin produced similar satisfactory clinical response rates against LRTIs, while meropenem appeared to be slightly more e¡ec-tive against intra-abdominal infections ( Table 2 ). All ¢ve patients with sepsis treated with meropenem had a satisfactory clinical response, compared with 40.0% (4/10) of those in the imipenem/cilastatin group ( Table 2) .
The overall satisfactory clinical response at the end of treatment in bacteriologically evaluable patients was 76.7% (56/73) in the meropenem group and 72.6% (53/73) in the imipenem/ cilastatin group. The respective response rates for meropenem and imipenem/cilastatin in the following infections were 69.2% (36/52) and 73.8% (31/42) for LRTI, 94.4% (17/18) and 82.6% (19/23) for intra-abdominal infections, and 100% (3/3) and 37.5% (3/8) for sepsis.
The overall satisfactory bacteriologic response rates at the end of treatment were 67.1% (49/73) in the meropenem group and 60.3% (44/73) in the imipenem/cilastatin group (di¡er-ence 6.9%; 95% CI, À8.7% to 22.4%; P 0.389). The two drugs showed similar bacteriologic e¤cacy against LRTIs and intra-abdominal infections, although meropenem produced a higher response rate in the small number of patients with sepsis ( Table 2) .
Similar percentages of isolated pathogens were eradicated (or presumed to be eradicated) by meropenem (88/108; 81.5%) and imipenem/cilastatin (94/128; 73.5%). The predominant pathogens were Enterobacteriaceae (Table 3) , against which meropenem appeared to be slightly more e¡ective than imipenem/cilastatin. Bacterial superinfection occurred in nine bacteriologically evaluable meropenem recipients and 11 of those who received imipenem/cilastatin (Table 4) .
Safety and tolerability
Both drugs were well tolerated. In the meropenem group, 66 adverse events were reported in 50 patients (46.7%), whereas 60 adverse events were noti¢ed in 44 patients (41.9%) treated with imipenem/cilastatin. Adverse events considered to be related to the study drug were reported in 3.7% (4/107) of patients treated with meropenem and 2.9% (3/105) of those who received imipenem/cilastatin. No incidences of drugrelated nausea and vomiting were reported in either group, but one probable drug-related seizure was reported in a patient treated with imipenem/cilastatin. Reasons for protocol violations necessitating exclusion from analysis: secondary infections (two patients with skin/skin structure infections and three with urinary tract infections), concomitant antibiotics at entry (6), fever of unknown origin at entry (1), and no ventilatory support LRTI patients (1) in the meropenem group; and secondary infection (2 patients with skin/skin structure infections), concomitant antibiotics at entry (3), fever of unknown origin at entry (1), and no ventilatory support LRTI patients (1) in the imipenem/cilastatin group. Reasons for clinical non-evaluability: death during therapy (2 patients), < 48 h monotherapy (2), known resistant pretherapy pathogens (1), amoebic infection (1), and vancomycin added for superinfection (1) in the meropenem group; and < 48 h monotherapy (5, of which 3 were due to death), known resistant pretherapy pathogens (1) and incorrect treatment regimen (1 day of meropenem) (1) in the imipenem/cilastatin group. a Colonization = any new organism isolated at the primary site but not requiring any additional antimicrobial therapy.
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There were nine deaths during therapy in the meropenem group (8.4% of recruited patients) and 14 (13.3%) in the imipenem/cilastatin group.
In the meropenem group there were six deaths (6/9; 66.7%) considered to be probably or possibly related to infection, versus 10 (10/14; 71.4%) in the imipenem/cilastatin group.
No deaths in either treatment group were considered to be related to study therapy. Death appeared to be related to pretherapyAPACHE II score, although the data are limited by the small numbers of patients involved [9] .
During the follow-up period, after the end of treatment, there were 22 deaths (20.6%) in the meropenem group and 14 in the imipenem/cilastatin group (13.3%). None of these deaths was considered to be drug-related. As most patients at this stage of their critical illness are heavily colonized and/or infected in one or several organ systems, it seems hazardous to directly attribute death to infection.
In the meropenem group, six deaths (27.3%) were probably not infection-related (acute vascular injury (n 1), cardiac arrest (n 1), brain damage (n 2), withdrawal of all therapy (n 2)); four deaths (18.1%) were probably infection-related (refractory septic shockötwo within 3 days post trial); and 12 deaths (54.6%) were possibly infection-related (single organ failureöacute respiratory distress syndrome (ARDS), acute renal failure (ARF)öor multiple organ failure (MOF)).
In the imipenem group, six deaths (42.9%) were probably not related to infection (cerebral damage (n 1), cardiac arrest (n 2), acute respiratory failure (n 3)); three deaths (21.4%) were probably infection-related (refractory septic shocköall within 5 days post trial); and ¢ve deaths (35.7%) were possibly related to infection (ARDS, MOF).
DISCUSSION
Meropenem monotherapy (1 g/8 h) has been shown to be at least as e¤cacious as combination antibacterial therapy in the treatment of a variety of infections, including nosocomial LRTI [12] , intra-abdominal infection [13, 14] and sepsis [15] . Previous randomized studies have shown meropenem and imipenem/cilastatin to be similarly e¤cacious at this dosage for the empirical treatment of serious infections in ICU patients [16^18] .
In the present study, meropenem produced a slightly higher overall satisfactory clinical response than imipenem/cilastatin (77.0% versus 68.1%), although the di¡erence did not reach statistical signi¢cance. This ¢nding does not appear to be related to any di¡erence between the patients in the two groups. Rather, analysis of the infection subgroups indicates that apparent di¡erences between the drugs in terms of their e¤cacy against intra-abdominal infection and sepsis were responsible for the slightly better overall satisfactory response rate with meropenem. However, the number of patients in some infection subgroups was small, particularly for those with sepsis.
The most common infection diagnosis was LRTI, and all of these patients were mechanically ventilated. Pneumonia is the hospital-acquired infection most likely to lead to the death of critically ill patients [19, 20] . Controversy remains about the most accurate way to diagnose this infection and the appropriate timing of antibiotic therapy in relation to the clinical suspicion of pneumonia [21] . Of all bronchoscopic and nonbronchoscopic diagnostic tests, endotracheal aspirate culture might be the most practical, and was mostly used in this study. Additional research is needed to determine the applicability of other diagnostic procedures in daily clinical practice. Some studies have shown that antibiotic therapy may have a favorable impact on the outcome of pneumonia, with lower mortality rates being observed if appropriate therapy is prescribed [22^24]. Recent trials have con¢rmed that timely and appropriate empirical antibiotic therapy is crucial and can improve survival in patients with pneumonia [25, 26] . The two carbapenems proved similarly e¤cacious in these patients. Interestingly, another recent study performed in seriously ill patients [18] noted a slightly better response rate with meropenem compared to imipenem/cilastatin in patients with nosocomial LRTIs (89% versus 76%). Unlike in the present study, however, not all patients with LRTIs in the study of Garau et al [18] were mechanically ventilated, which may explain the di¡er-ence in response rates. The severity of the underlying disease and acute illness of the a¡ected patients largely account for the poor outcome in the present study. Most infections are caused by Gram-negative bacilli, especially Pseudomonas species, and up to 55% of cases are caused by polymicrobial infection [27] . Prior antimicrobial therapy is a risk factor both for pneumonia and for infections with di¤cult-to-treat organisms, leading to poor response to therapy and a poor outcome [28] .
Di¡erences between treatment groups in the satisfactory bacteriologic response rates generally mirrored the clinical ¢ndings, with meropenem proving at least as e¤cacious as imipenem/cilastatin overall and for each infection subgroup. Eradication rates according to pathogen were generally as would be predicted from the in vitro spectra of the two carbapenems. Notable di¡erences, however, were the apparently more favorable results with meropenem against important Gram-negative ICU pathogens, particularly Escherichia coli, Enterobacter spp. and Pseudomonas aeruginosa. According to a similar study, both meropenem and imipenem/cilastatin proved highly e¡ective against the anaerobes, while a somewhat higher eradication rate of Gram-positive aerobes was observed in the imipenem/cilastatin group [16] .
Both drugs were well tolerated with regard to serious adverse events. The risk of seizures is a concern with higher doses of imipenem/cilastatin, especially in the presence of âòò Clinical Microbiology and Infection, Volume 6 Number 6, June 2000 impaired renal function and/or CNS disease [29] . However, patients with CNS disease were excluded from this study, and dosage reduction was performed according to the degree of renal impairment. This may explain why only one probable drug-related seizure was reported with imipenem/cilastatin. This compares with a seizure rate of 6% of patients receiving the same dosage of imipenem/cilastatin for the treatment of severe pneumonia [30] . The absence of seizures with meropenem is in line with the documented low seizurogenic activity of this agent in animal studies [31, 32] and in clinical trials that used doses up to 6 g/day [7] , some of which included patients with meningitis [33, 34] .
No drug-related instances of nausea or vomiting were reported in this study. Previous studies, mostly (but not exclusively) in neutropenic patients, have found nausea and vomiting to be a problem with imipenem/cilastatin [35^39]. In contrast, nausea and vomiting is not a signi¢cant problem with meropenem, even after bolus administration of the drug [7] . This adverse e¡ect, which appears to be related to the dosage and rate of infusion of imipenem/cilastatin [35, 40] , was avoided in this study by administering this agent slowly over 40^60 min. Meropenem was administered by bolus injection in almost 60% of patients in the present study. The option of bolus administration is particularly useful in ICU patients, in whom renal failure and left ventricular failure are common and £uid overload/hypervolemia must be avoided.
In summary, meropenem is at least as e¤cacious (clinically and bacteriologically) as imipenem/cilastatin for the empirical monotherapy of serious bacterial infections in ICU patients, and it can therefore be considered a useful option in this setting. Moreover, meropenem is well tolerated and o¡ers several potential advantages over imipenem/cilastatin, including greater in vitro activity against Gram-negative pathogens and the option of bolus administration.
